Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Prostatic Neoplasms × Radium-223 × Clear all

Phase

Phase 2 7 Phase 3 3 Phase 4 1 Phase 1/2 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Docetaxel 30 Prednisone 26 enzalutamide 17 Abiraterone Acetate 12 pembrolizumab 10 gallium 68 PSMA-11 9 Radiotherapy 8 Pluvicto 8 Magnetic Resonance Spectroscopy 8 Leuprolide 8 Estramustine 7 Nivolumab 6 Biopsy 6 olaparib 5 abiraterone 5 Specimen Handling 5 Paclitaxel 5 Goserelin 5 Carboplatin 5 orteronel 4 cemiplimab 4 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 4 Radiotherapy, Intensity-Modulated 4 Radiosurgery 4 Granulocyte-Macrophage Colony-Stimulating Factor 4 Cyclophosphamide 4 Androgen Antagonists 4 tremelimumab 3 radium Ra 223 dichloride 3 durvalumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05383079 2025-02-07

AlphaBet

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Active not recruiting

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡